AACR 2021: Human CD73 knock-in mice facilitate evaluation of in vivo efficacy of anti-human CD73 cancer immunotherapies
Hypoxia in the tumor microenvironment results in overexpression of CD73, which impairs immune function via adenosine receptors such as A2AR on immune cells. Biocytogen has…
Read more
AACR 2021: Evaluating anti-SIRPα in vivo efficacy in humanized B-NDG hSIRPA mice and B-NDG hSIRPA/hCD47 mice
CD47 binding to SIRPA results in inhibitory signals that protect cancer cells from phagocytosis by macrophages and other myeloid cells. Biocytogen generated humanized SIRPA and…
Read more
AACR 2021: TNFR2 and PD-1/PD-L1/TNFR2 humanized mice aid exploration of combination strategies to overcome tumor immune escape mechanisms
TNF signaling via TNFR2 plays an important role in modulation of the immune system via pro- and anti-inflammatory activities of T cells. Biocytogen has generated…
Read more
AACR 2021: Novel human B7-H3 knock-in mice demonstrate efficacy of anti-B7-H3 immunotherapy in vivo
Beyond its immune regulatory roles, B7-H3 can promote tumor growth, invasion, migration, angiogenesis, and metastasis. To investigate B7-H3 function in vitro and evaluate in vivo…
Read more
AACR 2021: A novel humanized B-hPD-1/hPD-L1/hTIGIT mouse model reveals enhanced efficacy of combined TIGIT and PD-L1 blockade against cancer
Competitive binding of TIGIT to CD155 and CD112 prevents signaling through CD226, which is an NK activating receptor that contributes to anti-tumor responses. Biocytogen established…
Read more
AACR 2021: SIGLEC15 humanized knock-in mice are a powerful tool to evaluate new therapies for cancer and osteoporosis
Non-redundant to PD-L1, SIGLEC15 interacts with CD8 T cells, which results in suppression of anti-tumor immune responses. Biocytogen has generated a humanized B-hSIGLEC15 mouse model,…
Read more
AACR 2021: Advancing Bispecific Antibody Discovery using a Common Light Chain Immunoglobulin Humanized Mouse
The common challenges of bispecific therapeutic antibody discovery are immunogenicity and chain mispairing issues. Biocytogen’s RenLiteTM immunoglobulin humanized mouse is designed not only to overcome…
Read more
AACR 2021: A Novel PD1-CD40 Bispecific Antibody YH008 Induces Potent Anti-tumor Activity in-vivo by PD1 Dependent Activation of CD40 Signaling
Immunotherapies that target PD1/PDL1 pathway have marked a new era of cancer therapy. Combinatorial treatment of inhibiting PD1/PDL1 signaling and other immunomodulating agents has been…
Read more
IO Summit: RenMab Mouse – A Leading Platform for Fully Human Antibody Generation
With the development of immuno-oncology, therapeutic antibodies have been proven to be extraordinarily effective for cancer treatment. Conventional human antibody discovery process can be divided…
Read more
IO Summit: B-NDG hIL-15 Mice Improve NK Cell Development After Human PBMC or CD34+ HSC Engraftment
Abstract Human HSC (hematopoietic stem cells) engrafted humanized mice are a powerful model that allows researchers to examine the human immune system and evaluate cellular…
Read more